NasdaqGM:AXSMPharmaceuticals
Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions
Axsome Therapeutics (NasdaqGM:AXSM) received U.S. FDA approval for AUVELITY for agitation associated with dementia due to Alzheimer’s disease.
AUVELITY becomes the first approved treatment in this indication, addressing a major unmet medical need.
The decision introduces a new commercial opportunity for Axsome in neuropsychiatric disorders.
Axsome’s AUVELITY approval comes with the stock at $216.47 and follows very large 3 year and 5 year share price gains, alongside a 96.5% return over the...